Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 11 art units • 15 examiners • 0 of 17 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Bms has 17 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 15 distinct examiners across 11 distinct art units, indicating a distributed prosecution profile with some repeated examiner and art-unit assignments. Counsel should combine centralized monitoring with focused review of recurring scientific and claim-scope issues.
DUFFY, BRADLEY is the busiest examiner, with 2 pending actions. The limited concentration may permit targeted coordination for those matters, but it does not define the broader portfolio. Art-unit patterns and application-specific prosecution histories should guide decisions on amendments, interviews, and response consistency.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (41%) |
| §112 only | 1 (6%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 4 (24%) |
| Multi-statute (no §101) | 4 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 2 | 54.4% | +46.0% |
| CANELLA, KAREN A | 2 | 62.3% | +32.8% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
| SONG, HOON K | 1 | 86.2% | +8.4% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.6% | +78.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18908717 | METHODS FOR DETECTING PARTICLES PRESENT IN A CELL COMPOSITION | SONG, HOON K | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | CANELLA, KAREN A | 63d |
| 18284800 | COMBINATION OF A CAR T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND FOR TREATMENT OF LYMPHOMA | SKOKO III, JOHN JOSEPH | — |
| 18280197 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | CANELLA, KAREN A | — |
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | DUNN, LINDSAY MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921614 | COMBINATION OF BCMA-DIRECTED T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | JOHNSON, CHRISTOPHER LINDSAY | 26d |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | CANELLA, KAREN A | 63d |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CHANDRAKUMAR, NIZAL S | 70d |
| 19312145 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | — |
| 18518384 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | — |
| 18491633 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY | DUFFY, BRADLEY | — |
| 18284800 | COMBINATION OF A CAR T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND FOR TREATMENT OF LYMPHOMA | SKOKO III, JOHN JOSEPH | — |
| 18283434 | METHODS OF DETERMINING POTENCY OF A THERAPEUTIC CELL COMPOSITION | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 5 |
| 1647 | 2 |
| 1638 | 2 |
| 1634 | 1 |
| 2884 | 1 |
| 1678 | 1 |
| 1644 | 1 |
| 1625 | 1 |
| 1691 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19312145 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Non-Final OA | — | Pending | Aug 27, 2025 |
| 18908717 | METHODS FOR DETECTING PARTICLES PRESENT IN A CELL COMPOSITION | SONG, HOON K | 2884 | DP | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18518384 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | 1647 | §103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18491633 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | — | Pending | Oct 20, 2023 |
| 18284800 | COMBINATION OF A CAR T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND FOR TREATMENT OF LYMPHOMA | SKOKO III, JOHN JOSEPH | 1643 | §103§112 | Final Rejection | — | Pending | Sep 28, 2023 |
| 18283434 | METHODS OF DETERMINING POTENCY OF A THERAPEUTIC CELL COMPOSITION | GAO, ASHLEY HARTMAN | 1678 | §103§112DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18280197 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | CANELLA, KAREN A | 1643 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | DUNN, LINDSAY MICHELLE | 1644 | §103§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CHANDRAKUMAR, NIZAL S | 1625 | §112Other | Final Rejection | 70d | Pending | May 03, 2023 |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | CANELLA, KAREN A | 1643 | §102§103§112Other | Non-Final OA | 63d | Pending | Mar 22, 2023 |
| 17921614 | COMBINATION OF BCMA-DIRECTED T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103DP | Non-Final OA | 26d | Pending | Oct 26, 2022 |
| 17774821 | COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4-YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDINE-2,6-DIONE | BUTTICE, AUDREY L | 1647 | §103Other | Final Rejection | — | Pending | May 05, 2022 |
| 17588149 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY | DUFFY, BRADLEY | 1643 | §103Other | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17297771 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | LU, CHENG | 1642 | §103DP | Final Rejection | — | Pending | May 27, 2021 |
| 17291536 | PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS | VAN BUREN, LAUREN K | 1638 | §103§112DP | Final Rejection | 19d | Pending | May 05, 2021 |
| 17266995 | METHODS FOR ASSESSING INTEGRATED NUCLEIC ACIDS | ZAHORIK, AMANDA MARY | 1636 | §103Other | Final Rejection | 27d | Pending | Feb 08, 2021 |
| 16609733 | COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | BURKHART, MICHAEL D | 1638 | §103 | Final Rejection | — | Pending | Oct 30, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBms has 17 pending office actions as of October 2026, spread across 11 art units and 15 examiners.
Bradley Duffy has the most, with 2 of Bms's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
